Ireland
--:--IST
Starting soon Not applicable

Treatment of Bulbar Urethral Strictures With Optilume Drug-Coated Balloons in an Untreated Population

NCT06827210 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2025-02-07
Last updated
2025-02-14

Condition(s) studied

Urethral StrictureUrethral Stricture, AnteriorUrethral Stricture, MaleUrethral Stricture Less Than 2 cm

Investigational drug(s) / intervention(s)

Optilume DCBStandard Direct Visual Internal Urethrotomy (DVIU)

Optilume DCB: Optilume DCB is a drug-coated balloon catheter designed for the treatment of bulbar urethral strictures. It combines mechanical dilation with localized drug delivery to reduce stricture recurrence and promote urethral healing. The balloon is coated with paclitaxel, an antiproliferative agent, to minimize scar tissue formation and improve treatment outcomes.

Standard Direct Visual Internal Urethrotomy (DVIU): Standard Direct Visual Internal Urethrotomy (DVIU), also known as Sachse Internal Urethrotomy, is a minimally invasive endoscopic procedure for treating urethral strictures.

Study summary

This randomized controlled trial investigates the effectiveness and safety of the Optilume® drug-coated balloon (DCB) compared to standard direct visual internal urethrotomy (DVIU) in the treatment of bulbar urethral strictures. The primary objective is to assess freedom from repeat intervention at 12 months. Secondary objectives include evaluating urethral patency, urinary symptoms, and sexual function through objective measures (Qmax, PVR, cystoscopy) and patient-reported outcomes (USS-PROM, IPSS, IIEF-5). The study will recruit 140 participants across multiple sites, with follow-ups conducted at 6 and 12 months. This trial seeks to provide evidence for Optilume DCB as a safe and effective alternative to standard treatment.

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male patients aged 18 years or older. * Diagnosed with a treatment-naive, single bulbar urethral stricture. * Stricture length ≤3 cm. * Eligible for local treatment with paclitaxel. * Able to provide written informed consent. Exclusion Criteria: * Female (chromosomal) sex. * History of prior urethral stricture or prior treatment thereof. * History of hypospadias repair. * History of genital lichen sclerosis. * Active or unresolved confounding etiology, including bladder neck contracture, neurogenic bladder, known or being evaluated for symptomatic benign prostatic hyperplasia (BPH) or surgical treatment for BPH within the last 5 years. * Known allergy or hypersensitivity to paclitaxel or any component of the Optilume DCB. * Known peripheral artery disease. * Severe comorbidities with an American Society of Anesthesiologists (ASA) score of 4 or higher. * Patients unable to comply with follow-up protocols or provide informed consent.

Primary outcome measure(s)

  • Freedom from Repeat Intervention at 12 Months — 12 months post-intervention
    "The primary outcome is the proportion of participants who remain free from repeat intervention for urethral stricture recurrence at 12 months following treatment. Repeat intervention is defined as any procedure to address stricture recurrence, such as dilation, DVIU, or urethroplasty. Referrals for repeat interventions made within the 12-month follow-up period will also be included, even if the procedure itself is scheduled beyond the 12-month mark."

Trial sites (3)

FacilityCityRegionStatus
Gødstrup Regional Hospital Gødstrup Central Jutland
Aalborg University Hospital Aalborg Region North Jutland
North Denmark Regional Hospital Hjørring Region North Jutland
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06827210 on ClinicalTrials.gov ↗ ← All trials in Denmark